Literature DB >> 29787816

O-GlcNAcylation and neuronal energy status: Implications for Alzheimer's disease.

Tiffany S Pinho1, Diogo M Verde1, Sónia C Correia1, Susana M Cardoso1, Paula I Moreira2.   

Abstract

Since the first clinical case reported more than 100 years ago, it has been a long and winding road to demystify the initial pathological events underling the onset of Alzheimer's disease (AD). Fortunately, advanced imaging techniques extended the knowledge regarding AD origin, being well accepted that a decline in brain glucose metabolism occurs during the prodromal phases of AD and is aggravated with the progression of the disease. In this sense, in the last decades, the post-translational modification O-linked β-N-acetylglucosaminylation (O-GlcNAcylation) has emerged as a potential causative link between hampered brain glucose metabolism and AD pathology. This is not surprising taking into account that this dynamic post-translational modification acts as a metabolic sensor that links glucose metabolism to normal neuronal functioning. Within this scenario, the present review aims to summarize the current understanding on the role of O-GlcNAcylation in neuronal physiology and AD pathology, emphasizing the close association of this post-translational modification with the emergence of AD-related hallmarks and its potential as a therapeutic target.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Aβ; Brain glucose metabolism; O-GlcNAc; O-GlcNAcylation; Tau

Mesh:

Substances:

Year:  2018        PMID: 29787816     DOI: 10.1016/j.arr.2018.05.003

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  5 in total

1.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

Review 2.  Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.

Authors:  Amy R Nelson
Journal:  Front Aging Neurosci       Date:  2022-04-18       Impact factor: 5.702

3.  O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.

Authors:  Bruno Permanne; Astrid Sand; Solenne Ousson; Maud Nény; Jennifer Hantson; Ryan Schubert; Christoph Wiessner; Anna Quattropani; Dirk Beher
Journal:  ACS Chem Neurosci       Date:  2022-03-31       Impact factor: 5.780

Review 4.  Glucose metabolic crosstalk and regulation in brain function and diseases.

Authors:  Shuai Zhang; Brittany Bolduc Lachance; Mark P Mattson; Xiaofeng Jia
Journal:  Prog Neurobiol       Date:  2021-06-10       Impact factor: 10.885

Review 5.  The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer's Disease.

Authors:  Vidyasagar Naik Bukke; Rosanna Villani; Moola Archana; Agata Wawrzyniak; Krzysztof Balawender; Stanislaw Orkisz; Luca Ferraro; Gaetano Serviddio; Tommaso Cassano
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.